First expert consensus backs ketogenic therapy for serious mental illness

Ketogenic therapy just crossed a line that matters: Georgia Ede and colleagues have published what they describe as the first peer-reviewed expert consensus paper on using keto to treat serious mental illness. The modified Delphi statement, in Frontiers in Nutrition, brought together an eight-expert steering group and turned a once-fringe conversation into a structured clinical framework for major depressive disorder, bipolar disorder and schizophrenia.

The panel developed 33 statements covering what ketogenic metabolic therapy is, which patients may be eligible, how to monitor it, and what best practices should look like. The consensus threshold was set at 75 percent, and every one of the 33 statements cleared it. That is the real shift here. This is no longer just a collection of anecdotes from people tinkering with macros and mood. It is a published attempt to give clinicians and patients a common language, a screening process, and a safety checklist.

The paper’s framing is blunt about why that matters. It says metabolic dysfunction is emerging as an important contributor to the pathophysiology of major depressive disorder, bipolar disorder and schizophrenia, and it points to the heavy burden these illnesses already impose through poor quality of life, reduced life expectancy and socioeconomic strain. It also notes that many patients never get meaningful relief from decades of medication-based care, while psychotropic drugs can bring serious metabolic side effects, including insulin resistance and obesity. For keto people, that part will sound familiar. For psychiatry, it is the kind of language that signals a field recalibrating.

This consensus did not come out of nowhere. A 2020 review by Zoltán Sarnyai and Christopher Palmer described ketogenic therapy in serious mental illness as emerging evidence and said the field was still early. Since then, the clinical signals have gotten harder to ignore. Stanford Medicine’s April 1, 2024 pilot followed 21 adults with schizophrenia or bipolar disorder and metabolic abnormalities, using a ketogenic diet built around roughly 10 percent carbohydrate, 30 percent protein and 60 percent fat. The study reported improvements in metabolic health and psychiatric symptoms.

A later bipolar disorder pilot, published online February 25, 2025, enrolled 27 participants, 26 started the diet and 20 finished it. Among completers, average body weight fell by 4.2 kg and systolic blood pressure dropped by 7.4 mmHg. The study also found decreases in brain glutamate plus glutamine of 11.6 percent in the anterior cingulate cortex and 13.6 percent in the posterior cingulate cortex. Add in a 2024 randomized trial protocol and a schizophrenia study listed on ClinicalTrials.gov, and the picture is clear: ketogenic therapy for serious mental illness is moving from pilot territory into formal testing. It is not standard care yet, but it is no longer easy to dismiss as a passing experiment.